Literature DB >> 19779697

Bronchoalveolar lavage fluid peptidomics suggests a possible matrix metalloproteinase-3 role in bronchopulmonary dysplasia.

Giovanni Vento1, Chiara Tirone, Paola Lulli, Ettore Capoluongo, Franco Ameglio, Simona Lozzi, Francesco Cota, Fabio Mosca, Costantino Romagnoli, Irene Messana, Massimo Castagnola, Rosanna Inzitari.   

Abstract

BACKGROUND: Bronchoalveolar lavage fluid (BALF) is an important diagnostic source to investigate molecular changes occurring in lung disorders. The objective of this study was to assess and compare the peptidomic profiles of BALF from premature neonates with and without bronchopulmonary dysplasia (BPD).
METHODS: Samples were obtained on the 3rd day of life from 34 neonates with gestational age <or=32 weeks. Two pools of samples from patients with and without BPD were analyzed by high performance liquid chromatography. Several differentially expressed peptides were collected and sequenced. Moreover, samples from single donors were analyzed by liquid chromatography-electrospray ionization mass spectrometry to define the molecular mass values of various peptides and to quantify their expression. Levels of some matrix metalloproteinases and their tissue inhibitors were also determined in single samples.
RESULTS: Neonates of the BPD group (N = 16) showed significantly lower mean gestational age and birth weight with respect to the no-BPD group (N = 18; P < 0.0001). Levels of six peptides were significantly higher in BPD patients (P < 0.05). Two of them were identified as the albumin fragments 1-21 (2,428 Da) and 399-406 (956 Da). Levels of matrix metalloproteinase-3 (MMP-3) enzyme probably involved in albumin fragment generation were also significantly higher in the BPD group compared to the no-BPD group (P < 0.05), whereas the levels of tissue inhibitor of metalloproteinases-1 were significantly lower (P < 0.05). Levels of albumin fragments and MMP-3 showed a significant correlation (P < 0.05).
CONCLUSIONS: This study shows that proteomic techniques can be applied to investigate the involvement of proteolytic enzymes on the airways of mechanically ventilated premature infants.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779697     DOI: 10.1007/s00134-009-1646-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  33 in total

1.  Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study.

Authors:  Barbara Magi; Luca Bini; Maria Grazia Perari; Antonella Fossi; Jean-Charles Sanchez; Denis Hochstrasser; Salvo Paesano; Roberto Raggiaschi; Annalisa Santucci; Vitaliano Pallini; Paola Rottoli
Journal:  Electrophoresis       Date:  2002-09       Impact factor: 3.535

2.  Role of stromelysin 1 and gelatinase B in experimental acute lung injury.

Authors:  R L Warner; L Beltran; E M Younkin; C S Lewis; S J Weiss; J Varani; K J Johnson
Journal:  Am J Respir Cell Mol Biol       Date:  2001-05       Impact factor: 6.914

Review 3.  Proteomics: current techniques and potential applications to lung disease.

Authors:  Jan Hirsch; Kirk C Hansen; Alma L Burlingame; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-07       Impact factor: 5.464

Review 4.  Definitions and diagnostic criteria for bronchopulmonary dysplasia.

Authors:  Eduardo Bancalari; Nelson Claure
Journal:  Semin Perinatol       Date:  2006-08       Impact factor: 3.300

5.  Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants.

Authors:  B H Su; T Watanabe; M Shimizu; M Yanagisawa
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

6.  Validity of markers of dilution in small volume lung lavage.

Authors:  P A Dargaville; M South; P Vervaart; P N McDougall
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

7.  Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress.

Authors:  K Cederqvist; T Sorsa; T Tervahartiala; P Maisi; K Reunanen; P Lassus; S Andersson
Journal:  Pediatrics       Date:  2001-09       Impact factor: 7.124

8.  Bronchoalveolar lavage fluid proteins in human lung disease: analysis by two-dimensional electrophoresis.

Authors:  A G Lenz; B Meyer; U Costabel; K Maier
Journal:  Electrophoresis       Date:  1993-03       Impact factor: 3.535

9.  The role of matrix metalloproteinases -9 and -2 in development of neonatal chronic lung disease.

Authors:  D G Sweet; A E Curley; E Chesshyre; J Pizzotti; M S Wilbourn; H L Halliday; J A Warner
Journal:  Acta Paediatr       Date:  2004-06       Impact factor: 2.299

10.  Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease.

Authors:  Ikechukwu I Ekekezie; Donald W Thibeault; Stephen D Simon; Michael Norberg; Jeffrey D Merrill; Roberta A Ballard; Philip L Ballard; William E Truog
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

View more
  14 in total

1.  Benefits of pre-, pro- and Syn-biotics for lung angiogenesis in malnutritional rats exposed to intermittent hypoxia.

Authors:  Asma Ahmad; Charles L Cai; Dharmendra Kumar; Fayme Cai; Antoni D'Souza; Lawrence Fordjour; Taimur Ahmad; Gloria B Valencia; Jacob V Aranda; Kay D Beharry
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Early biomarkers as predictors for bronchopulmonary dysplasia in preterm infants: a systematic review.

Authors:  Zhi-Qun Zhang; Xian-Mei Huang; Hui Lu
Journal:  Eur J Pediatr       Date:  2013-09-01       Impact factor: 3.183

3.  Reactive Oxygen Species, Biomarkers of Microvascular Maturation and Alveolarization, and Antioxidants in Oxidative Lung Injury.

Authors:  Arwin M Valencia; Maria A Abrantes; Jamal Hasan; Jacob V Aranda; Kay D Beharry
Journal:  React Oxyg Species (Apex)       Date:  2018-11

4.  Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells.

Authors:  Naoko Yamakawa; Tokujiro Uchida; Michael A Matthay; Koshi Makita
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-21       Impact factor: 5.464

Review 5.  Year in review in Intensive Care Medicine 2009. Part III: mechanical ventilation, acute lung injury and respiratory distress syndrome, pediatrics, ethics, and miscellanea.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-02-23       Impact factor: 17.440

6.  Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect.

Authors:  Kazuo Ogawa; Tatsushi Omatsu; Chinami Matsumoto; Naoko Tsuchiya; Masahiro Yamamoto; Yuji Naito; Toshikazu Yoshikawa
Journal:  BMC Complement Altern Med       Date:  2012-08-09       Impact factor: 3.659

Review 7.  Bronchopulmonary dysplasia early changes leading to long-term consequences.

Authors:  Anne Hilgendorff; Michael A O'Reilly
Journal:  Front Med (Lausanne)       Date:  2015-02-12

8.  Transcriptome Analysis of the Preterm Rabbit Lung after Seven Days of Hyperoxic Exposure.

Authors:  Thomas Salaets; Jute Richter; Paul Brady; Julio Jimenez; Taro Nagatomo; Jan Deprest; Jaan Toelen
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

9.  Bioinformatics insights into acute lung injury/acute respiratory distress syndrome.

Authors:  Xiaocong Fang; Chunxue Bai; Xiangdong Wang
Journal:  Clin Transl Med       Date:  2012-06-09

Review 10.  Albumin and multiple sclerosis.

Authors:  Steven M LeVine
Journal:  BMC Neurol       Date:  2016-04-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.